Skip to main content
Equibles

ENLV · Enlivex Ltd.

Track ENLV — free

Use ENLV with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research ENLV.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$0.22 +0.02 (+7.86%) At close · Oct 20
Rebalance outlook locked
Market Cap
$4.45M
Shares
19.91M
Volume · Oct 20 444.39K Avg daily vol (3M) 1.04M

Price & Indicators

Drag to pan · scroll to zoom
Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$0.22 Open$0.22 Day$0.21–0.23 52W close$0.21–18.15 Avg vol 30d1.8M Short int99K · 0.5% float · 1.0d Short vol24% Last earningsMar 25, 2026 DataJan 2020–Oct 2026

Up next

Q4 2025 earnings call transcript
call held Mar 25, 2026

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
—
Trailing 12 months
Net income (TTM)
$3.19B
Trailing 12 months
Revenue growth YoY
—
Year over year
Operating margin
—
Trailing 12 months
P / E (TTM)
0.0
Trailing earnings · reciprocal yield 77,255.1%
FCF yield
-377.0%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+1,115.7%
Year over year · more shares
Price change (1Y)
—
Trailing year
Short interest
0.5%
Latest settlement · 1.0 days to cover
View all 122 metrics

Equibles Rating

blended score · not investment advice
Overall
Sell
SellHoldBuy
Technical Sell Momentum Very Weak Sentiment Bearish Fundamentals Strong Quant / Vol Very High
Market backdrop VIX 17.3 · elevated Equity put/call 0.56
Technical
price trend
Sell
50 / 200-day cross No cross
Price vs 200-day avg −98%
below
Price vs 50-day avg −75%
below
RSI (14) 15
oversold
MACD trend Positive
52-week position 0%
near low
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Very Weak
1-month return −65%
trailing
6-month return −98%
trailing
YTD return −98%
this year
Relative strength −106%
vs S&P · 6-mo
Sentiment
smart money
Bearish
Trend (MA cross) No cross
50d $1 › 200d $9 — 200d above 50d
Institutional flow Distributing
1 of 27 funds reported for Sep 30 · net -1 sh shares
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
0.50% of float · ▲ +104.5% MoM · 1.0 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
27 holders — mid 3-yr range
Squeeze score 46
elevated · 0–100
Fundamentals
Strong
EPS growth +3590%
Y/Y
Free cash flow $-10.5M
Balance sheet $1.9M
net cash
Quant / Vol
risk profile
Very High
Volatility 98%
annualized · 1-yr
Max drawdown −99%
past year
ATR 36.8%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Sell
3 · 3 · 1
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
−98% Bearish
Price vs 50-day avg
−75% Bearish
RSI (14)
15 Neutral
MACD trend
Positive Bullish
52-week position
0% Bearish
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Bearish · 2 of 6
Trend (MA cross) No cross
50d $1 › 200d $9 — 200d above 50d
Institutional flow Distributing
1 of 27 funds reported for Sep 30 · net -1 sh shares
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
0.50% of float · ▲ +104.5% MoM · 1.0 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
27 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $0 Now $0 · 0% Range high $18
vs 200-day avg -98% vs 50-day avg -75%

Illustrative technical + ownership context — a signal mix, not investment advice.

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
ENLV
Enlivex Ltd.
this stock
$4.45M — — — 0.5%
VRTX
Vertex Pharmaceuticals Inc / Ma
 $130.07B +13.5% +46.2% 29.9 1.8%
MRNA
Moderna, Inc.
 $90.58B +720.9% +4.3% — 7.7%
REGN
Regeneron Pharmaceuticals, Inc.
 $80.51B +4.6% +20.8% 19.4 2.1%
CSLLY
Csl Ltd
 $66.34B — — — 0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Reducing
Holders
27
% held
1.5%
Reported
1 of 27
Top holder
ARK Investment Management…
Held Float
View
Short & Settlement
Short Interest Rising
Shares short
98.6K
Days to cover
1.0d
Change
+50.4K sh
View
Short Volume
Short vol %
24%
As of
Oct 20, 2026
Short Total
View
Fails to Deliver
FTD shares
9.8K
Value
$5.1K
As of
Sep 29, 2026
View
Off-Exchange
Off-exchange %
61.6%
Week of
Sep 14, 2026
Off-exch Lit
View
Financials
Financials
Net income (FY)
$1.2B
EPS diluted
$382.20
View
Filings
SEC Filings
Latest
6-K
Filed
Oct 19, 2026
This year
35

Enlivex announced a cost reduction plan on October 19, 2026, cutting its workforce by approximately 60%, winding down non-clinical R&D, and reducing management salaries by 20% and the CEO's by 40% to fund its Phase 2b Allocetra™ knee osteoarthritis trial, with topline data expected by mid-2027.

View
Earnings & Events
Webcasts
Last webcast
Mar 25, 2026
View

Performance

5D 20D 120D MTD YTD
ENLV +0.6% -65.4% -98.1% -55.5% -97.9%
SPY -1.2% -0.6% +8.1% +0.8% +12.8%
vs SPY +1.7% -64.8% -106.2% -56.4% -110.7%
Key facts CIK 1596812 CUSIP M4130Y171 13F (30d) 1 filings 1 filers Visit website Investor relations